Aurobindo Pharma Q4FY26 Net Profit Up 2% YoY

Aurobindo Pharma reported Q4FY26 revenue growth of 5.6% YoY to ₹8,853 Cr, with European business crossing €1bn+ in annual revenues.
Net profit increased 2.0% YoY to ₹921 Cr, while EBITDA margin contracted by 104 bps YoY to 20.3% for the quarter.
The company received 9 ANDA approvals from USFDA and maintained a strong net cash position after acquiring Khandelwal Labs for $317mn.
Operational performance showed strong growth in Europe (30.2% YoY) and Growth Markets (24.7% YoY), while US formulations declined 13.0% YoY.